Tesirine| SG3249;SG-3249

Cas No.:	1595275-62-9
Chemical Name:	Tesirine
Synonyms:	Tesirine;MP-PEG8-VA-PABC-PBD Dimer;8DVQ435K46;SG3249;N-[31-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-29-oxo-4,7,10,13,16,19,22,25-octaoxa-28-azahentriaconta
SMILES:	O([H])[C@@]1([H])[C@]2([H])C([H])([H])C(C([H])([H])[H])=C([H])N2C(C2=C([H])C(=C(C([H])=C2N1C(=O)OC([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])N([H])C([C@]([H])(C([H])([H])[H])N([H])C([C@]([H])(C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C(C([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])N([H])C(C([H])([H])C([H])([H])N1C(C([H])=C([H])C1=O)=O)=O)=O)=O)=O)OC([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])OC1=C(C([H])=C2C(=C1[H])N=C([H])[C@]1([H])C([H])([H])C(C([H])([H])[H])=C([H])N1C2=O)OC([H])([H])[H])OC([H])([H])[H])=O
Formula:	C₇₅H₁₀₁N₉O₂₃
M.Wt:	1496.6510
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Tesirine ( SG3249) is a cathepsin B-cleavable valine-alanine pyrrolobenzodiazepine (PBD) dimer as antibody-drug conjugate (ADC) payload; Tesirine (SG3249) was designed to combine potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics; Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and expressed in small-cell lung cancer.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC74470	SuO-Val-Cit-PAB-MMAE	A drug-linker conjugate for antibody-drug conjugate by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the cleavable peptide SuO-Val-Cit-PAB..
DC72532	Fmoc-VAP-MMAE	Fmoc-VAP-MMAE is a drug-linker conjugates for ADC. Fmoc-VAP-MMAE consists of an ADC linker and a tubulin inhibitor MMAE, with a protective Fmoc group.
DC72119	Deruxtecan analog 2	Deruxtecan analog 2 (example 9 P3) is a Deruxtecan analog. Deruxtecan analog 2 is a drug-linker conjugate composed of Camptothecin and a linker. Camptothecin (CPT) is a Topo I inhibitor with antineoplastic activity against colorectal, breast, lung and ovarian cancers. Deruxtecan analog 2 can be used for the preparation anti-FGFR2 ADC.
DC71950	Ac-Lys-Val-Cit-PABC-MMAE	Ac-Lys-Val-Cit-PABC-MMAE is a drug-linker conjugate for ADC. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitor MMAE.
DC71666	MC-VA-PABC-MMAE	MC-VA-PABC-MMAE is a drug-linker conjugate for ADC. MC-VA-PABC-MMAE contains the ADCs linker (peptide MC-VA-PABC) and a potent tubulin polymerization inhibitor MMAE.
DC71665	Val-Cit-PAB-MMAF	Val-Cit-PAB-MMAF is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAF contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF.
DC71664	Val-Cit-PAB-MMAF sodium	Val-Cit-PAB-MMAF sodium is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAF sodium contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF.
DC71115	SN38 NHS ester	SN38 NHS ester is the NHS ester derivative of SN38. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis. SN38 NHS ester can be used for the synthesis of antibody-drug conjugates (ADCs).
DC50214	MC-Val-Cit-PAB-DX8951	MC-Val-Cit-PAB-DX8951 is a drug-linker conjugate for ADC. MC-Val-Cit-PAB-DX8951 is composed of a DNA topoisomerase I DX-8951 and a cathepsin cleavable ADC linker.
DC47680	PSMA-Val-Cit-PAB-MMAE	PSMA-Val-Cit-PAB-MMAE is a novel small-molecule PSMA-targeted conjugate based on the monomethyl auristatin E for the chemotherapy of prostate cancer.